Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AXN-2510 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on AXN-2510, a putative bispecific antibody targeting CD274 (PD-L1) and VEGF (Sep 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AXN-2510 | AXN 2510|AXN2510 | PD-L1/PD-1 antibody 132 VEGF Antibody 15 | Limited information is currently available on AXN-2510, a putative bispecific antibody targeting CD274 (PD-L1) and VEGF (Sep 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07159828 | Phase I | AXN-2510 | A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |